



VACCI-TEST™

C O R P O R A T I O N

FOR IMMEDIATE RELEASE - Calgary, Alberta- June 21st, 2006

VTC signs Exclusive Agreement with Axcell for 1st Commercial Product

Vacci-Test™ Corporation ("VTC") is pleased to announce its first commercial infectious disease diagnostic product for the global market place. The disease, known as Leptospirosis, is a serious, often misdiagnosed infectious disease common in sanitation, dairy and packing house workers. It can be spread through contaminated or polluted bodies of water. This zoonotic disease can be easily treated with antibiotics. However, if left untreated it can result in serious damage to the kidneys, liver, brain or heart and in severe cases be fatal in both humans and animals.

The test product has two applications and will be known as Vacci-Test™ SPIROLEPT® for vaccination screening of Leptospirosis; and Vacci-Test™ LEPTOSPIROSIS for the identification of the disease in humans. VTC signed the agreement with Axcell Biotechnologies ("Axcell") based in St Genis l'Argentière, France, where VTC granted Axcell exclusive licensing rights to manufacture, bring to market and service the product in France and Switzerland.

Vacci-Test™ SPIROLEPT® will determine the need for a vaccination; while Vacci-Test™ LEPTOSPIROSIS, which will measure the amount of circulating antibodies in the blood. Vacci-Test™ "SPIROLEPT®" will be marketed in a kit with Axcell's unique Spirolept Vaccine. VTC and Axcell plan to have these tests on the market by the end of September 2006. William Hogan, President & CEO of VTC stated, "This innovative two in one product is the first in a series of several diagnostics tests including App and Brucellosis for swine and Tetanus for humans that VTC plans to have on the market in the next 6-12 months".

"This Agreement is just the first step of a long and prosperous relationship" remarked Jean-Marc Verniere, President & CEO of Axcell. "I am very pleased with the agreement and this formal undertaking between our two companies is just the first step into what I want to see grow into an ongoing and prosperous relationship." Dr. Jacques Mayet, CSO of VTC stated, "This partnership between VTC and Axcell creates an alliance with the ability to quickly enter and capture markets for diagnostic tests."

VTC is researching and developing innovative screening kits for the rapid detection of infectious diseases and/or the precise evaluation of immune level status in humans and animals, both through a simple blood test. VTC plans to introduce several validated Vacci-Test™ products in 2006, including App (a pneumonia swine infection); Brucellosis (a swine infection that causes abortion); and Tetanus for humans. A key test in development is a non-laboratory lateral flow strip test, which will enable veterinarians to detect Transmissible Spongiform Encephalopathy (TSE) brain infections. This test will use an independently discovered marker in the blood and will specifically detect *BSE* in cattle and *variant Creutzfeldt - Jakob disease* in humans.

AXCELL BIOTECHNOLOGIES is a pharmaceutical company in St Genis l'Argentière, France (located close to the city of Lyon) which will assume production of the Vacci-Test™ series of products for VTC. Axcell has a laboratory/manufacturing facility that specializes in the manufacture of small and medium-sized quantities of sterile products. The entire organization of Axcell has been developed around an outstanding control laboratory. The quality of the system that has been implemented allowed Axcell to obtain the distinction of "Pharmaceutical Establishment" for products for human usage; ISO 9002 certification; as well as GMP/GLP certification (Good Manufacturing Practices / Good Laboratory Practices). The overall business strategy designed by VTC will see Axcell take charge of the initial production of the Vacci-Test™ series of products for both human and veterinary applications.

For more information contact: William J. Hogan, President & CEO or The Honourable Charlie Mayer, Director or visit www.vaccitest.com.

Vacci-Test™ Corporation
Suite 340, 550 - 11th Avenue S.W.
Calgary, Alberta, Canada T2R 1M7
Canada Toll Free: 1-877-298-0208
Bus: (403) 269-9424 Fax: (403) 263-6357
www.vaccitest.com